TROP2 gets more crowded
The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.
November's CHMP meeting sets up a GSK-Novartis battle
Novartis' Jakafi faces competition from GSK's momelotinib, while Astra looks over its shoulder at Merck in biliary tract cancer.
World Lung 2023 – targeted therapy to the rescue in small-cell lung
Adding a kinase inhibitor to PD-L1 plus chemo could make a real difference in first-line SCLC, a little-appreciated Chinese trial suggests.
